Labetalol

Oral tablets treat hypertension to lower blood pressure. The selected IV product controls blood pressure in severe hypertension and is intended for hospitalized patients. Pediatric safety and effectiveness are not established. Pregnancy-specific emergency algorithms and off-label indications are not supplied here.

Selected vial solution is 5 mg/mL. One label preparation adds 200 mg in 40 mL to 160 mL compatible fluid, giving 200 mL at 1 mg/mL; 2 mL/min delivers 2 mg/min. Titrate infusion to pressure response; usual effective IV total is 50–200 mg, with up to 300 mg required in some patients. The label also has a distinct approximate-concentration preparation; pump settings are concentration specific. Hospital transition begins when supine diastolic pressure rises: initial oral 200 mg, then 200 or 400 mg after 6–12 hours by response; inpatient titration differs from routine outpatient starts.

The selected oral SPL gives severe-hypertension and older-adult details in highlights while its full dosage body contains only the ordinary-start subsection; these highlighted rules are identified above. No age/weight pediatric schedule, universal renal/hepatic adjustment or pregnancy emergency conversion is invented.

Oral labeling lists asthma/obstructive airway disease, decompensated heart failure, greater-than-first-degree block, cardiogenic shock, severe bradycardia, labetalol hypersensitivity and non-dihydropyridine calcium-channel antagonists. IV labeling lists asthma, overt failure, advanced block, shock, severe bradycardia, severe/prolonged hypotension and ingredient hypersensitivity; it also warns against obstructive airway disease. Formal interaction wording differs; do not treat an older IV caution as permission to combine contraindicated oral therapy.

Neither selected label has a boxed warning. Withdrawal-related ischemia, serious liver injury and cardiac/airway contraindications remain clinically important.

Common reported oral effects include fatigue, nausea and dizziness; headache, dyspepsia, nasal stuffiness and dyspnea also occur. IV treatment can cause marked postural hypotension, scalp tingling, nausea and infusion-related hemodynamic changes. Serious reported events include bradycardia/block, syncope, failure, bronchospasm, allergy and liver injury. Rates across settings are not directly comparable.

Oral co-use with non-dihydropyridine calcium antagonists such as verapamil is contraindicated; other negative chronotropes increase bradycardia/hypotension risk. Beta blockade antagonizes beta-agonist bronchodilation. Nitroglycerin adds hypotension; the oral label advises avoiding initiation in patients with angina on nitroglycerin and monitoring established combinations. Cimetidine can increase oral bioavailability; anesthesia can augment hypotension.

The selected injection is incompatible with 5% sodium bicarbonate; alkaline drugs such as furosemide can precipitate in the same line. Use only verified admixture compatibility. Labetalol can cause false-positive amphetamine screens and interfere with some urinary catecholamine assays; confirm with a specific method rather than infer substance use or pheochromocytoma from an affected screening assay.

The current oral label summarizes extensive pregnancy use without an identified major-malformation signal, while acknowledging study limitations and inconsistent other outcomes. The older clinical IV text uses a limited-controlled-evidence benefit/risk formulation; no zero-risk claim follows. Placental exposure can cause neonatal hypotension, bradycardia, hypoglycemia or respiratory depression. Labetalol occurs in milk at low levels; oral infant/milk-production outcome data remain lacking and IV labeling advises caution. Consider maternal need and feeding benefits with clinical review.

Pediatric safety/effectiveness are unestablished in the selected labels. Older adults eliminate labetalol more slowly and often need lower maintenance doses; monitor orthostatic symptoms closely.

No numeric organ-adjustment table is supplied. Hepatic impairment can increase oral bioavailability by reducing first-pass metabolism; IV labeling advises caution with impaired hepatic function. Monitor renal/clinical status where relevant. Hemodialysis and peritoneal dialysis remove less than 1% and are not effective routine clearance methods.

Labetalol competitively blocks alpha-1 and nonselective beta receptors; estimated alpha-to-beta effects differ after oral versus IV administration. Standing pressure can fall more than supine pressure.

Oral peaks occur around one to two hours and absolute bioavailability is about 25%; food increases bioavailability. Oral half-life is about six to eight hours; IV infusion half-life about 5.5 hours. Approximately half is protein bound; glucuronidation predominates, with urinary and biliary elimination. Hepatic impairment can change oral exposure despite similar reported half-life.

Monitor BP/pulse/rhythm and signs of failure or bronchospasm; review glucose risks and liver symptoms such as jaundice, dark urine or persistent anorexia. IV labeling supports hepatic tests and immediate testing for suggestive symptoms. Keep patients supine during and immediately after IV therapy, up to three hours, then observe first ambulation. Review medication adherence and avoid unsupervised interruption; inform surgical teams.

Excess dosing can cause profound posture-sensitive hypotension, bradycardia and other beta-blockade toxicity; seek emergency/Poison Control assessment. Dialysis removes little drug. Selected labels contain older induced-emesis and emergency-treatment wording; this profile does not endorse home emesis or replace a current toxicology protocol.

Oral product

Remedy 100 mg tablet · NDC 70518-4201-00, bottle 180

Oral appearance

Round beige, scored; I / 126

Injection

Hospira 5 mg/mL IV multiple-dose vial

Example IV package

100 mg / 20 mL · NDC 0409-2267-20

Oral section three describes 100, 200 and 300 mg tablets, while this selected repackaged supply record supplies 100 mg. The selected injection supplies 100 mg / 20 mL and 200 mg / 40 mL at 5 mg/mL. Ready-made premix products, their concentrations and container instructions are not reviewed here.

Selected tablets: 20–25°C in a tight light-resistant container with required child-resistant closure. Injection: 20–25°C; protect from light and freezing. Selected compatible diluted admixtures are labeled stable twenty-four hours refrigerated or at room temperature; this is not universal compatibility or a beyond-use date for every preparation.